Raspberry Pharma

Pharmaceutical products and manufacturing services in India.

About Raspberry Pharma

Raspberry Pharma is an Industrial Goods & Manufacturing company. Pharmaceutical products and manufacturing services in India. It operates in the Industrial Goods & Manufacturing and Healthcare sectors. Its Indian entity Raspberry Pharmaceuticals Private Limited reported revenue of β‚Ή26.6 Lakh. Raspberry Pharma offers products and services including BERRYXIME-200 and LICO DX SYRUP. Its focus areas include Manufacturing Services, Contract Manufacturing, Third-Party Production and Pharmaceuticals.

Company details

Raspberry Pharma is recognized as a pharmaceutical company in India that provides high-quality healthcare solutions with integrity. A distinctive product line is offered primarily to general practitioners, gynecologists, pediatricians, and specialized physicians, focusing on managing chronic and metabolic disorders, critical care, and vitamin supplements. Vertically integrated operations are maintained, including in-house formulation development, regulatory affairs, manufacturing, and quality assurance. It is noted for serving as a reliable supplier in contract manufacturing, ensuring products are delivered effectively to meet patient needs. This approach supports the delivery of specialized goods in the healthcare sector.

Key Metrics
  • Indian entity revenue
    ₹26.6 Lakh

    FY 2025 · +132% YoY

  • Indian entity net profit
    ₹55,672

    FY 2025 · 2% margin

  • Indian entity EBITDA
    ₹62,592

    FY 2025 · 2% margin

Products & Services of Raspberry Pharma

Raspberry Pharma offers a comprehensive portfolio of products and services, including BERRYXIME-200 and LICO DX SYRUP.

BERRYXIME-200
Pharmaceutical Products

This product is utilized for therapeutic purposes in healthcare settings.

LICO DX SYRUP
Syrups

This syrup is employed for addressing specific health needs in medical practice.

Board of directors of Raspberry Pharmaceuticals Private Limited (Raspberry Pharma)

Raspberry Pharmaceuticals Private Limited is the primary company behind Raspberry Pharma. The board of Raspberry Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Ram Kailash Dangi, appointed in 2023. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ram Kailash Dangi
DIN 10258990
Director28 Jul 20233 yrs 3 moRaspberry Pharmaceuticals Private Limited
Prashant Gupta
DIN 10442996
Director01 Dec 202511 moRaspberry Pharmaceuticals Private Limited

Financials of Raspberry Pharma

Figures of Raspberry Pharmaceuticals Private Limited, the primary company behind Raspberry Pharma, for FY 2025. Revenue was ₹26.6 Lakh (+132% year on year). Net profit was ₹55,672 (2% margin). EBITDA was ₹62,592 (2% margin).

  • ₹26.6 LakhRevenue · FY 2025 · +132% YoY
  • ₹55,672Net profit · 2% margin
  • ₹62,592EBITDA · 2% margin
  • ₹2 LakhPaid-up capital

Balance sheet, profit and loss, cash flow and ratios of Raspberry Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Raspberry Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Raspberry Pharma

The primary company behind Raspberry Pharma, Raspberry Pharmaceuticals Private Limited, reported revenue of β‚Ή26.6 Lakh for FY 2025, up 132% year on year.

Raspberry Pharma is recognized as a pharmaceutical company in India that provides high-quality healthcare solutions with integrity. A distinctive product line is offered primarily to general practitioners, gynecologists, pediatricians, and specialized physicians, focusing on managing chronic and metabolic disorders, critical care, and vitamin supplements. Vertically integrated operations are maintained, including in-house formulation development, regulatory affairs, manufacturing, and quality assurance. It is noted for serving as a reliable supplier in contract manufacturing, ensuring products are delivered effectively to meet patient needs. This approach supports the delivery of specialized goods in the healthcare sector.

Raspberry Pharma offers BERRYXIME-200 and LICO DX SYRUP.

Raspberry Pharma operates through Raspberry Pharmaceuticals Private Limited.

The legal entities of Raspberry Pharma currently have 2 directors, including Ram Kailash Dangi, Prashant Gupta.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available